Bioengineer Gang Bao uses gene editing to repair up to 40 percent of bone marrow cells from patients
Scientists have successfully used gene editing to repair 20 to 40 percent of stem and progenitor cells taken from the peripheral blood of patients with sickle cell disease, according to Rice University bioengineer Gang Bao.
Bao, in collaboration with Baylor College of Medicine, Texas Children’s Hospital and Stanford University, is working to find a cure for the hereditary disease. A single DNA mutation causes the body to make sticky, crescent-shaped red blood cells that contain abnormal hemoglobin and can block blood flow in limbs and organs.
In his talk at the annual American Association for the Advancement of Science meeting in Austin Feb. 16, Bao revealed results from a series of tests to see whether CRISPR/Cas9-based editing can fix the mutation. His presentation was part of a scientific session titled “Gene Editing and Human Identity: Promising Advances and Ethical Challenges.”
“Sickle cell disease is caused by a single mutation in the beta-globin gene (in the stem cell’s DNA),” he said. “The idea is to correct that particular mutation, and then stem cells that have the correction would differentiate into normal blood cells, including red blood cells. Those will then be healthy blood cells.”
Bao’s lab collaborated with Vivien Sheehan, an assistant professor of pediatrics and hematology at Baylor and a member of the sickle cell program at Texas Children’s, to collect stem and progenitor cells (CD34-positive cells) from patients with the disease. These were then edited in the Bao lab with CRISPR/Cas9 together with a custom template, a piece of DNA designed to correct the mutation.
The gene-edited cells were injected into the bone marrow of immunodeficient mice and tested after 19 weeks to see how many retained the edit. “The rate of repair remained stable, which is great,” Bao said. This engraftment study was carried out in the lab of Matt Porteus, an associate professor of pediatrics at Stanford.
Another major finding of the study is that the CRISPR/Cas9 system could introduce large alterations to the genes in patients’ cells, in addition to small mutations or deletions. These off-target effects could cause a disease.
The findings, part of an upcoming paper, are a step toward treating sickle cell disease. Obstacles in the way of a cure include optimizing the CRISPR/Cas9 system to eliminate off-target effects, as well as finding a way to further increase the amount of gene-corrected stem cells.
Bao pointed out that researchers still don’t know whether repairing as much as 40 percent of the cells is enough to cure a patient. “We’d like to say, ‘Yes,’” he said, “but we don’t really know yet. That’s something we hope to learn from an eventual clinical trial.”
The Latest on: Sickle cell disease
Patients Discharged From the Emergency Department After Referral for Hospitalist Admission
on March 17, 2018 at 9:19 am
Chest pain was the most common diagnosis. Those with alcohol-related diagnoses, abdominal pain, and sickle cell disease with crisis were more likely to return to the ED, whereas those presenting with chest pain were less likely. Those with Medicare and ... […]
Global sickle cell disease drug market explored in latest research
on March 16, 2018 at 1:51 am
Sickle Cell Disease Drug Market is provided in the report based on product scope and market status & outlook. The market is segmented on the basis of type, end-users/application, and geography. The report provides information about the production, price ... […]
Modified Hopkins conditioning may improve donor engraftment for sickle cell disease
on March 14, 2018 at 5:07 am
SALT LAKE CITY — An altered version of the Hopkins conditioning regimen may lead to more stable donor engraftment without severe toxicity among patients with sickle cell disease who undergo haploidentical hematopoietic stem cell transplantation ... […]
African-American Senators Seek Sickle-Cell Funds
on March 13, 2018 at 6:15 pm
Not all genetic diseases, however, so successfully capture the public imagination. Despite being one of the most common genetic diseases in the country, sickle-cell disease (SCD) has garnered far less attention—and funding—than comparable genetic diseases. […]
The future is now: Editing DNA to treat disease
on March 13, 2018 at 2:10 pm
This story is sponsored by University of Utah Health. Sickle cell disease is the most common blood disorder in the United States, affecting approximately 100,000 Americans. It is caused by a gene mutation that makes red blood cells collapse from a circle ... […]
Director Chosen For New UTHSC Sickle Cell Disease Center
on March 13, 2018 at 1:12 pm
The University of Tennessee Health Science Center has launched a new Center for Sickle Cell Disease in the College of Medicine and tapped a leader for it who will come on board in July. Dr. Kenneth Ataga will direct the center, which is a collaborative ... […]
Tracing sickle cell back to one child, 7,300 years ago
on March 12, 2018 at 6:21 pm
New research suggests that the history of sickle-cell disease goes back to a mutation in just one person, a development researchers hope will make treatment less complicated for the many people who suffer from this painful illness. So how have they traced ... […]
Scott, Booker introduce sickle cell disease legislation
on March 6, 2018 at 9:15 pm
WASHINGTON, D.C. - U.S. Senators Tim Scott (R-SC) and Cory Booker (D-NJ) have introduced a new initiative in the fight against sickle cell disease – the Sickle Cell Disease Research, Surveillance, Prevention and Treatment Act. There is currently no ... […]
Clinical trial offers hope to adults with sickle cell disease
on March 5, 2018 at 9:24 pm
At 33, Alexis Jones-Heggs has known a life filled with “regular crises.” Times when she was unable to walk or sit up straight or even use her hands to eat. High school graduation, when she’d just gotten out of the hospital and says she “limped all ... […]
via Google News and Bing News